Kingswood Wealth Advisors LLC purchased a new position in iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE – Free Report) in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 3,100 shares of the company’s stock, valued at approximately $203,000.
A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Grimes & Company Inc. bought a new stake in shares of iShares U.S. Pharmaceuticals ETF in the second quarter worth $1,468,000. Wealthcare Advisory Partners LLC increased its stake in iShares U.S. Pharmaceuticals ETF by 4.3% during the second quarter. Wealthcare Advisory Partners LLC now owns 4,898 shares of the company’s stock valued at $321,000 after purchasing an additional 201 shares during the last quarter. Ameritas Advisory Services LLC bought a new stake in iShares U.S. Pharmaceuticals ETF during the second quarter valued at $169,000. Truist Financial Corp increased its stake in iShares U.S. Pharmaceuticals ETF by 2.8% during the second quarter. Truist Financial Corp now owns 9,104 shares of the company’s stock valued at $593,000 after purchasing an additional 252 shares during the last quarter. Finally, Capital Investment Advisors LLC increased its stake in iShares U.S. Pharmaceuticals ETF by 28.7% during the second quarter. Capital Investment Advisors LLC now owns 7,124 shares of the company’s stock valued at $467,000 after purchasing an additional 1,588 shares during the last quarter.
iShares U.S. Pharmaceuticals ETF Price Performance
IHE stock opened at $74.04 on Friday. iShares U.S. Pharmaceuticals ETF has a 1-year low of $58.97 and a 1-year high of $76.14. The firm has a fifty day moving average price of $70.77 and a two-hundred day moving average price of $67.48. The firm has a market cap of $596.02 million, a price-to-earnings ratio of 17.75 and a beta of 0.70.
iShares U.S. Pharmaceuticals ETF Company Profile
iShares U.S. Pharmaceuticals ETF, formerly iShares Dow Jones U.S. Pharmaceuticals Index Fund (the Fund), is an exchange traded fund. The Fund seeks investment results that correspond generally to the price and yield performance of the Dow Jones U.S. Select Pharmaceuticals Index (the Index). The Index measures the performance of the pharmaceuticals sector of the United States equity market, and includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines, but excludes producers of vitamins.
Featured Stories
- Five stocks we like better than iShares U.S. Pharmaceuticals ETF
- Airline Stocks – Top Airline Stocks to Buy Now
- Bassett Furniture: Buy Now, Sit Back, and Collect Dividends
- Ride Out The Recession With These Dividend KingsĀ
- AST SpaceMobile’s Big Win: Shares Soar on New Deal With Verizon
- About the Markup Calculator
- Catch the Next Bitcoin Rally With These 3 ETFs
Receive News & Ratings for iShares U.S. Pharmaceuticals ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares U.S. Pharmaceuticals ETF and related companies with MarketBeat.com's FREE daily email newsletter.